Literature DB >> 21233092

Angiotensin-converting enzyme gene and plasma protein level in Alzheimer's disease in Taiwanese.

Yuan-Han Yang1, Chiou-Lian Lai, Yu-Chang Tyan, Mei-Chuan Chou, Ling-Chun Wang, Ming-Hui Yang, Ching-Kuan Liu.   

Abstract

BACKGROUND: angiotensin-converting enzyme (ACE) gene insertion/deletion (indel) polymorphism is considered a biomarker for Alzheimer's disease (AD). However, the associations of ACE gene and protein level to AD are undetermined among Taiwanese.
METHODS: this study investigated 257 Taiwanese cases with AD and 137 ethnically matched controls using ACE gene indel genotype association methods with logistic regression adjusted for other variables. Besides, 65 out of 257 AD patients, 11 with D/D genotype, 28 with I/I genotype and 26 with I/D genotype were recruited. Their plasma ACE protein levels were measured by enzyme-linked immuno-sorbent assay and compared for their corresponding ACE gene indel polymorphism.
RESULTS: patients with ACE-I/I homozygote were less likely to be associated with AD, compared with both I/D and D/D (OR: 0.601; 95% CI: 0.372-0.969; P = 0.037), or only I/D genotype (OR: 0.584; 95% CI: 0.349-0.976; P = 0.040). There were significantly different plasma ACE protein levels among these three different genotype groups (P = 0.023). The I/I genotype group had significantly lower ACE plasma levels [114.79 ± 31.32 ng/ml (mean ± SD)], compared with D/D (164.07 ± 86.36 ng/ml; P = 0.010), but not I/D (141.45 ± 51.50 ng/ml; P = 0.064).
CONCLUSION: ACE-I/I homozygote corresponds to lower plasma ACE protein level and it is independently but less likely to be associated with AD. These findings signal the importance of ACE indel polymorphisms to their corresponding protein levels and to AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233092     DOI: 10.1093/ageing/afq179

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  6 in total

1.  Hypertension and longevity: role of genetic polymorphisms in renin-angiotensin-aldosterone system and endothelial nitric oxide synthase.

Authors:  Alda Pereira da Silva; Andreia Matos; Laura Aguiar; Nuno Ramos-Marques; Ricardo Ribeiro; Ângela Gil; João Gorjão-Clara; Manuel Bicho
Journal:  Mol Cell Biochem       Date:  2018-11-20       Impact factor: 3.396

2.  Angiotensin-converting enzyme gene insertion-deletion polymorphism is a risk marker for Alzheimer's disease in a Chinese population: a meta-analysis of case-control studies.

Authors:  Ye Yuan; Jin-hua Piao; Ke Ma; Na Lu
Journal:  J Neural Transm (Vienna)       Date:  2015-01-18       Impact factor: 3.575

3.  Angiotensin-converting enzyme insertion/deletion polymorphism is not a major determining factor in the development of sporadic Alzheimer disease: evidence from an updated meta-analysis.

Authors:  Xue-bin Wang; Ning-hua Cui; Jie Yang; Xue-ping Qiu; Jia-jia Gao; Na Yang; Fang Zheng
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

4.  Biomarkers and Gene Polymorphisms in Members of Long- and Short-lived Families: A Longevity Study.

Authors:  Vana Kolovou; Olga Diakoumakou; Athanasia K Papazafiropoulou; Niki Katsiki; Elisabeth Fragopoulou; Ioannis Vasiliadis; Dimitris Degiannis; Leonidas Duntas; Smaragdi Antonopoulou; Genovefa Kolovou
Journal:  Open Cardiovasc Med J       Date:  2018-07-31

5.  Angiotensin-converting enzyme polymorphisms AND Alzheimer's disease susceptibility: An updated meta-analysis.

Authors:  Xiao-Yu Xin; Ze-Hua Lai; Kai-Qi Ding; Li-Li Zeng; Jian-Fang Ma
Journal:  PLoS One       Date:  2021-11-24       Impact factor: 3.240

Review 6.  Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases.

Authors:  Sonia Mayo; Julián Benito-León; Carmen Peña-Bautista; Miguel Baquero; Consuelo Cháfer-Pericás
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.